(CercleFinance.com) – PCAS, a specialist in complex molecules for the life sciences and technology sector, announced on Wednesday evening that Seqens, its majority shareholder, plans to launch a takeover bid for the 23.3% capital that he does not yet hold.
The pharmaceutical synthesis giant, which already holds 77.7% of the capital, intends to offer eight euros per PCAS share, representing a premium of 7.4% compared to the last closing price before the announcement of the offer, i.e. 7.45 euros.
PCAS adds that Seqens intends to proceed, at the end of its simplified purchase offer, with a capital increase of around 200 million euros in order to reduce the company’s indebtedness and strengthen its own funds.
These announcements come as PCAS announced that it had returned to profit over the first six months of the year, with an operating profit of 36.4 million euros against a loss of 30 million a year earlier.
Net profit stood at 25.4 million euros in the first half compared to a loss of 32.2 million euros in the first half of 2022.
PCAS shares were suspended from trading on Thursday on Euronext Paris, a decision effective yesterday until further notice.